U.S. Markets close in 52 mins

Predilife S.A. (ALPRE.PA)

Paris - Paris Delayed Price. Currency in EUR
6.20-0.10 (-1.59%)
At close: 05:35PM CET

Predilife S.A.

39, Rue Camille Desmoulins
Villejuif 94805
33 09 72 22 67 08

IndustryDiagnostics & Research
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephane RagusaFounder, Pres, CEO & Chairman150kN/A1970
Mr. Émilien GauthierChief Technical Officer and R&D DirectorN/AN/AN/A
Marion RenelierLegal DirectorN/AN/AN/A
Anne KerzanChief Marketing OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Corporate Governance

Predilife S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.